L’Oréal’s strategic venture capital fund, BOLD, has acquired a minority stake in Timeline, a Swiss longevity biotech company.
 
Timeline was founded in 2007 by Chris Rinsch (Co-Founder and President) and Patrick Aebischer (Co-Founder and Chairman) to develop innovative solutions for longevity in the food, beauty and health sectors.
 
Timeline has developed a proprietary molecule, Mitopure, that recycles and rejuvenates aging mitochondria, the powerhouses of cells. This breakthrough technology is backed by more than a decade of research by scientists, multiple gold standard clinical studies, and a strong intellectual property portfolio.
 
The investment will enable Timeline to further develop its unique technology and expand operations, while enabling future collaboration with L’Oréal.
 
“Longevity is about living healthier for longer and L’Oréal has been working for more than a decade to understand and anticipate what this could mean for beauty,” said Barbara Lavernos, Deputy Chief Executive Officer and in charge of Research, Innovation and Technology, L’Oréal Groupe. “Longevity adds a new dimension to beauty, focused on predicting, correcting and even reversing the ageing of our skin, scalp and hair. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”
 
“This strategic collaboration reflects the breakthrough multidimensional approach that we’ve always believed is necessary to make meaningful advancements for longevity and healthspan,” said Patrick Aebischer, Co-Founder and Chairman of Timeline. “I want to thank L’Oréal for its commitment to longevity solutions rooted in the highest level of science.”

Other BOLD Investments